Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Immuneering Corporation - Class A Common Stock
(NQ:
IMRX
)
6.730
-0.080 (-1.17%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 26, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immuneering Corporation - Class A Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026
December 23, 2025
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA
December 17, 2025
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)
December 16, 2025
From
Immuneering Corporation
Via
GlobeNewswire
Earnings Scheduled For November 12, 2025
↗
November 12, 2025
Via
Benzinga
Why Immuneering Stock Soared Over 40% After-Hours Today
↗
September 24, 2025
Via
Stocktwits
Immuneering Inks Supply Agreement With Eli Lilly For Latter’s Investigational Cancer Therapy: Retail Looks To Buy The Stock On Dips
↗
August 25, 2025
Via
Stocktwits
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference
November 25, 2025
From
Immuneering Corporation
Via
GlobeNewswire
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
November 19, 2025
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:ALXO),(NASDAQ:ERAS),(NASDAQ:IMRX),(NASDAQ:PRLD) EQNX::TICKER_END
Via
FinancialNewsMedia
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
November 19, 2025
From
FN Media Group LLC
Via
GlobeNewswire
Immuneering (IMRX) Q3 2025 Earnings Transcript
↗
November 13, 2025
Immuneering (IMRX) Q3 2025 Earnings Transcript
Via
The Motley Fool
Topics
Intellectual Property
Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates
November 12, 2025
From
Immuneering Corporation
Via
GlobeNewswire
A Preview Of Immuneering's Earnings
↗
November 11, 2025
Via
Benzinga
Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025
November 04, 2025
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Corporation's Stock Takes a Hit Amidst Funding Round Despite Promising Clinical Data
September 27, 2025
Boston, MA – September 27, 2025 – Immuneering Corporation (NASDAQ: IMRX) experienced a significant downturn in its stock value on September 25, 2025, with shares declining by approximately 13.3%. This...
Via
MarketMinute
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
September 26, 2025
From
Immuneering Corporation
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
September 25, 2025
Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session. The market value of their outstanding shares is at $87.2 million.
Via
Benzinga
Why PepGen Shares Are Trading Higher By 112%; Here Are 20 Stocks Moving Premarket
↗
September 25, 2025
Shares of PepGen Inc. (NASDAQ: PEPG) rose sharply in pre-market trading after the company announced the launch of an underwritten public offering of common stock and pre-funded warrants.
Via
Benzinga
Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi
September 25, 2025
From
Immuneering Corporation
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
September 24, 2025
Via
Benzinga
Top movers in Wednesday's after hours session
↗
September 24, 2025
After the closing bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Via
Chartmill
Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
September 24, 2025
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi
September 24, 2025
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Appoints Dr. Thomas Schall as Chairman of the Board
September 16, 2025
From
Immuneering Corporation
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
September 10, 2025
Via
Benzinga
Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25
September 10, 2025
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Announces Closing of $25 Million Private Placement
August 26, 2025
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib
August 25, 2025
From
Immuneering Corporation
Via
GlobeNewswire
Top stock movements in today's session.
↗
August 21, 2025
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.
Via
Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
August 21, 2025
Via
Benzinga
Top movers analysis in the middle of the day on 2025-08-21: top gainers and losers in today's session.
↗
August 21, 2025
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
